Asset profile
Dapagliflozin · Farxiga / Forxiga
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Chronic Kidney Disease, Type 2 Diabetes, Heart Failure
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atherosclerotic Cardiovascular Disease · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
229 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 218 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dapagliflozin (Farxiga / Forxiga): this drug | Approved | Small molecule | SGLT2 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| DWP16001 (Enavogliflozin) | Phase 3 | Small molecule | SGLT2 | ||
| Janagliflozin | Phase 3 | Small molecule | SGLT2 | ||
| THR-1442 | Phase 3 | Small molecule | SGLT2 | ||
| DA-2811 | Phase 2 | Small molecule | SGLT2 | ||
| Tofogliflozin (Apleway / Deberza) | Phase 2 | Small molecule | SGLT2 | ||
| Rongliflozin | Phase 1 | Small molecule | SGLT2 | ||
| Zibotentan + Dapagliflozin | Phase 3 | Small molecule | Endothelin A receptor, SGLT2 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor |
…and 214 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Bexagliflozin · Type 2 Diabetesvs Canagliflozin · Type 2 Diabetes +1vs Empagliflozin · Type 2 Diabetes +2vs Ertugliflozin · Type 2 Diabetesvs DWP16001 · Type 2 Diabetesvs janagliflozin · Type 2 Diabetes
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(87 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (19)
October 2026 (5)
Phase 3AMI, STEMI, NSTEMI, Left Ventricular DysfunctionRecruiting
Est. primary completion 2026-10-12 · NCT05764057 · CT.gov ↗
What to watch
Phase 2/3Type 2 DiabetesActive not recruiting
Est. primary completion 2026-10-18 · NCT07033585 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2026-10-30 · NCT07026968 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2026-10-30 · NCT07351643 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-10-31 · NCT06560801 · CT.gov ↗
What to watch
November 2026 (4)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-11-04 · NCT06772168 · CT.gov ↗
What to watch
Phase 1/2DepressionRecruiting
Est. primary completion 2026-11-20 · NCT07239011 · CT.gov ↗
What to watch
Phase 2/3Atrial Fibrillation Recurrent, Catheter AblationActive not recruiting
Est. primary completion 2026-11-30 · NCT06111443 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2026-11-30 · NCT06954090 · CT.gov ↗
What to watch
December 2026 (10)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12 · NCT07311551 · CT.gov ↗
What to watch
Phase 4Heart FailureActive not recruiting
Est. primary completion 2026-12-01 · NCT06578520 · CT.gov ↗
What to watch
Phase 1Kidney FailureRecruiting
Est. primary completion 2026-12-03 · NCT07754331 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2026-12-10 · NCT07222917 · CT.gov ↗
What to watch
Phase 1Dapagliflozin (Forxiga), Atrial Fibrillation (AF)Not yet recruiting
Est. primary completion 2026-12-22 · NCT06759909 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06155604 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2026-12-31 · NCT06304857 · CT.gov ↗
What to watch
Phase 3Pediatric Hereditary Kidney DiseasesRecruiting
Est. primary completion 2026-12-31 · NCT06890143 · CT.gov ↗
What to watch
Phase 4Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF), Pulmonary Regurgitation, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor …Recruiting
Est. primary completion 2026-12-31 · NCT06668389 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07595289 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
February 2027 (3)
Early phase / not applicableHeart FailureRecruiting
Est. primary completion 2027-02-28 · NCT06868797 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-02-28 · NCT02969798 · CT.gov ↗
What to watch
April 2027 (3)
Phase 2Renal AL AmyloidosisRecruiting
Est. primary completion 2027-04 · NCT06420167 · CT.gov ↗
What to watch
Phase 3Diabetes Mellitus, Atrial FibrillationRecruiting
Est. primary completion 2027-04 · NCT05174052 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2027-04-16 · NCT06307652 · CT.gov ↗
What to watch
May 2027 (3)
Phase 3Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-05-01 · NCT07598864 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2027-05-30 · NCT07405216 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-05-31 · NCT06610526 · CT.gov ↗
What to watch
June 2027 (4)
Phase 3ST Elevation Myocardial Infarction, Myocardial InfarctionRecruiting
Est. primary completion 2027-06 · NCT06174753 · CT.gov ↗
What to watch
Phase 3Type 1 DiabetesRecruiting
Est. primary completion 2027-06-01 · NCT07056699 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT07614230 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06-30 · NCT06054035 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
Phase 2/3Ascites HepaticRecruiting
Est. primary completion 2027-07 · NCT07684326 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2027-07 · NCT05374291 · CT.gov ↗
What to watch
Phase 2Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu ArteritisRecruiting
Est. primary completion 2027-07-01 · NCT06887062 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionRecruiting
Est. primary completion 2027-08-01 · NCT07776054 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (3)
Phase 2GlomerulonephritisNot yet recruiting
Est. primary completion 2027-11 · NCT07096986 · CT.gov ↗
What to watch
Phase 4MASH - Metabolic Dysfunction-Associated SteatohepatitisNot yet recruiting
Est. primary completion 2027-11 · NCT07848191 · CT.gov ↗
What to watch
Phase 4Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07436663 · CT.gov ↗
What to watch
December 2027 (8)
Phase 1Breast Cancer, Hyperinsulinism, HER2-negative Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05989347 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-12 · NCT06072326 · CT.gov ↗
What to watch
Phase 2Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, AnatomicalRecruiting
Est. primary completion 2027-12 · NCT07174687 · CT.gov ↗
What to watch
Phase 3Atrial Fibrillation (AF)Recruiting
Est. primary completion 2027-12 · NCT07187570 · CT.gov ↗
What to watch
Early phase / not applicableHeart FailureNot yet recruiting
Est. primary completion 2027-12 · NCT07392788 · CT.gov ↗
What to watch
Early phase / not applicableHeart FailureNot yet recruiting
Est. primary completion 2027-12 · NCT07403955 · CT.gov ↗
What to watch
Phase 3Chronic Coronary Syndrome, Atrial FibrillationRecruiting
Est. primary completion 2027-12-04 · NCT05852704 · CT.gov ↗
What to watch
Phase 4Myocardial InfarctRecruiting
Est. primary completion 2027-12-31 · NCT06562582 · CT.gov ↗
What to watch
2028 (19)
January 2028 (1)
Phase 2/3Heart FailureNot yet recruiting
Est. primary completion 2028-01-31 · NCT07469722 · CT.gov ↗
What to watch
February 2028 (2)
June 2028 (4)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-06 · NCT07239570 · CT.gov ↗
What to watch
Phase 4Kidney Transplant; Complications, Kidney Transplant Failure, Renal FailureRecruiting
Est. primary completion 2028-06 · NCT05788276 · CT.gov ↗
What to watch
Phase 1Lung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-29 · NCT07235280 · CT.gov ↗
What to watch
Phase 3COVID - 19, Long COVID Syndrome, SARS CoV-2Not yet recruiting
Est. primary completion 2028-06-30 · NCT06907251 · CT.gov ↗
What to watch
July 2028 (3)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-07-05 · NCT07662109 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2028-07-14 · NCT07662044 · CT.gov ↗
What to watch
August 2028 (3)
Phase 4Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular ComplicationRecruiting
Est. primary completion 2028-08 · NCT06785116 · CT.gov ↗
What to watch
Early phase / not applicableTakotsubo CardiomyopathyRecruiting
Est. primary completion 2028-08-09 · NCT07491718 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2028-08-31 · NCT07273838 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Heart Transplant Failure, Kidney FailureActive not recruiting
Est. primary completion 2028-09-30 · NCT05321706 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Kidney Transplant; Complications, Vascular Diseases, DiabetesRecruiting
Est. primary completion 2028-10-31 · NCT06140537 · CT.gov ↗
What to watch
November 2028 (2)
2029 (12)
January 2029 (2)
March 2029 (1)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
July 2029 (2)
August 2029 (3)
Phase 2Aortic StenosisNot yet recruiting
Est. primary completion 2029-08 · NCT07539259 · CT.gov ↗
What to watch
Phase 3Septic ShockNot yet recruiting
Est. primary completion 2029-08 · NCT07488689 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-08-01 · NCT07254572 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-09-01 · NCT07108985 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Prostate Cancer, Metastatic Prostate CancerNot yet recruiting
Est. primary completion 2029-10-30 · NCT07310433 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Phase 3Polycystic Kidney, Autosomal DominantRecruiting
Est. primary completion 2030-05-15 · NCT07280585 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-07-01 · NCT07624305 · CT.gov ↗
What to watch
October 2030 (1)
Phase 4Chronic Hepatitis BRecruiting
Est. primary completion 2030-10-31 · NCT06364930 · CT.gov ↗
What to watch
2031 (1)
March 2031 (1)
Phase 1Pediatric Brain Tumor, Pediatric Solid TumorRecruiting
Est. primary completion 2031-03-31 · NCT05521984 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.